Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.32 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037055 | 0.64 | — | — | |
| Water SCHEMBL30202303 | 0.45 | — | — | |
| Water SCHEMBL29409691 | 0.45 | — | — | |
| Water SCHEMBL29349940 | 0.45 | — | — | |
| Water SCHEMBL29774211 | 0.45 | — | — | |
| Water SCHEMBL30171254 | 0.45 | — | — | |
| Water SCHEMBL30543095 | 0.45 | — | — | |
| Water SCHEMBL30475397 | 0.45 | — | — | |
| Water SCHEMBL31217747 | 0.45 | — | — | |
| Water SCHEMBL29381358 | 0.45 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735424-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250042906-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20250034154-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2025006998-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006946-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | Theravance Biopharma R&D LP, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11566168-B1 | Biocide blend for treating wellbores | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230026695-A1 | BIOCIDE BLEND FOR TREATING WELLBORES | HALLIBURTON ENERGY SERVICES, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2023287453-A1 | BIOCIDE BLEND FOR TREATING WELLBORES | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | JAK1, JAK3, JAK2 | MEN1 1827/4885PTGS1 1010/4885ALDH1A1 2732/4885 |
| US-20250042906-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | MEN1 3102/4885PTGS1 3692/4885ALDH1A1 4273/4885 |
| US-20250034154-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | IRAK4, IRAK2, IRAK3 | MEN1 4220/4885PTGS1 3008/4885ALDH1A1 3949/4885 |
| US-20230026695-A1 | BIOCIDE BLEND FOR TREATING WELLBORES | KAT2B, WEE2, OTUB1 | MEN1 2876/4885PTGS1 4622/4885ALDH1A1 2687/4885 |
| US-11566168-B1 | Biocide blend for treating wellbores | KAT2B, WEE2, OTUB1 | MEN1 2876/4885PTGS1 4622/4885ALDH1A1 2687/4885 |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | JAK1, JAK3, JAK2 | MEN1 1827/4885PTGS1 1010/4885ALDH1A1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.